Base to Base Biotech

Times: 02:58 Deep Science Ventures 22:16 4basebio This week, we have a conversation with Amy Walker, CEO of 4basebio, and Adam Tomassi-Russell, senior director, climate, at Deep Science Ventures. 4basebio 4basebio is a UK-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4ba...

This week, we have a conversation with Jeff Fischer, president of Longhorn Vaccines & Diagnostics, and with Hannah Amies, founder and CEO of Luvida. Times: 03:03 Longhorn Vaccines and Diagnostics 25:03 Luvida Longhorn Vaccines & Diagnostics on breakthroughs in molecular testing Maryland-based Longhorn Vaccines and Diagnostics is a IND-enabling stage biopharmaceutical company developing vac...

This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold. Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an oversubscribed pre-seed round. The funding enables Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time. The platfor...

This week on Base to Base, we have a conversation with Bora Pharmaceuticals’ chief commercial officer Jean-Baptiste (JB) Agnus. Bora Pharmaceuticals Bora Pharmaceuticals is an international contract development and manufacturing organization (CDMO) specialising in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics...

This week, we have a conversation with Mark Sawicki, president and CEO of Cryoport Systems, and we chat with Nick Manusos, CEO of Kenai Therapeutics. Times: 03:22 Cryoport Systems 22:24 Kenai Therapeutics Cryoport Systems Cryoport Systems provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of sensiti...

This week, we have a conversation with Revalesio president Greg Archambeau about tackling strokes, and other conditions, with a novel method. Revalesio While the pharmaceutical industry often focuses on complex chemical compounds, Revalesio is pioneering a novel drug class rooted in a surprising field: fluid physics. Revalesio is also focusing on stroke, a condition in need of new therapies. Reval...

This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop Oncology. Times: 03:23 Kazia Therapeutics 31:56 PureTech Health PureTech Health PureTech Health plc is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming...

This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster. Alessa Therapeutics Alessa Therapeutics recently announced positive preliminary phase 1 safety and efficacy data for its prostate cancer treatment Enolen. This was the first study to demonstrate that the FDA-approved prostate cancer compound enzalutamide can be safely a...

This week, we have a conversation with DIA chief science and regulatory officer, Maria Vassileva, and Medicus Pharma CEO, Raza Bokhari. Times: 02:53 Medicus Pharma 29:13 DIA DIA DIA (Drug Information Association) is a global organisation that assists life science professionals from across all areas of expertise to engage with patients, peers and thought leaders in a neutral environment on the issu...

This week, we have a conversation with congenital myotonic dystrophy patient advocacy consultant Lisa Harvey-Duren, who was the founding Myotonic Dystrophy Foundation executive director in 2008, and Michael Snape, CEO and CSO of AMO Pharma, which is developing a treatment for the disease. AMO Pharma AMO Pharma is a clinical-stage specialty biopharmaceutical company working to identify and advance...

This week, our conversations are with Uwe Diegel, CEO of Lifeina, about their cooling technologies, and with Dirk Beher, CEO of FundaMental Pharma, about treatment resistant depression. Times: 02:37 FundaMental Pharma 23:56 Lifeina FundaMental FundaMental Pharma is a preclinical biopharmaceutical company focused on developing new treatments for treatment‑resistant depression (TRD). The company’s p...

This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel Vitt, CEO of Immunic. Times: 02:54 Immunic 24:04 Neurvati Neurosciences/GRIN Therapeutics GRIN Therapeutics GRIN Therapeutics Inc. is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders with the goal of bringin...

This week, our conversations are with Steve Perrin, president and CSO of Eledon Pharmaceuticals, and Jason Bock, CEO and co-founder of CTMC. Times: 03:18 CTMC 35:46 Eledon Pharmaceuticals CTMC CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change in real time without charge ups and allowing for better control...

This week, because April 11 is World Parkinson’s Day, we chat with Dieter Willbold, CSO of Priavoid, and Antje Willuweit, director preclinical development of Priavoid, and Karsten Eastman, CEO and co-founder of Sethera Therapeutics, about the company’s work on peptides. Times: 02:52 Sethera Therapeutics 22:35 Priavoid Priavoid Priavoid , a company advancing novel disease-modifying approaches for n...

On this week’s episode, as April 2 is World Autism Day, we have a conversation with Manish Arora, CEO of LinusBio, on its test that can rule out if someone has autism, and we talk to Thomas Kledal, CEO of Synklino, about improving kidney transplantation outcomes through better cytomegalovirus (CMV) prevention. Times: 03:18 LinusBio 35:43 Synklino LinusBio LinusBio has expanded access to its ClearS...

On this week’s episode, we chat with Hans Eriksson, chief medical officer (CMO) of HMNC Brain Health, about ketamine and treatment-resistant depression, and with Krishna Polu, CEO, president and co-founder of new kidney health biotech company R1 Therapeutics. Times: 03:57 HMNC Brain Health 29:47 R1 Therapeutics HMNC Brain Health HMNC Brain Health is a Munich-based clinical-stage biopharma company...

On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director of oncology at CureLab Oncology Inc., about elanagen, a promising therapeutic advance for women with platinum-resistant ovarian cancer; Eden Ben, CEO of Amorphical, about nano-amorphous mineral therapeutics inspired by blue crayfish; and Hans Schambye, CEO of BOOST Pharma...

As this week’s podcast comes hot on the heels of International Women’s Day and World Kidney Day, which was yesterday, we’ve been able to squeeze them both in. The conversations this week are with Hansa Biopharma CEO Renée Aguiar-Lucander, about imlifidase for kidney transplant patients; Kyron.bio CEO Emilia McLaughlin, about glycosylation; and hydrogel-based drug delivery solutions company AmacaTh...

This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with Pahini Pandya, Panakeia CEO, about colorectal cancer biomarkers, the potential of AI in clinical decision-making and how AI can transform workflows in diagnostics. Times: 03:34 Purespring 24:11 Panakeia Technologies Purespring Therapeutics Purespring is a precision nephrolo...

The conversations on this week’s podcast are with CEO of Merz Therapeutics, Stefan König, about a variety of neurodegenerative conditions and a botulinum neurotoxin, and with CEO of Kainova Therapeutics, Sean MacDonald, about – among other things – G-protein coupled receptors, or GPCRs. Times: 03:21 Merz Therapeutics 30:34 Kainova Therapeutics Kainova Therapeutics Kainova Therapeutics is a clinica...

The conversations on this week’s podcast focus on a rapid and accurate prostate cancer diagnostic test, with Valley Diagnostics’ CEO Dave Taylor; and on gene therapy for retinal disease, with Lance Baldo, CEO of Beacon Therapeutics. Times: 03:12 Beacon Therapeutics 27:38 Valley Diagnostics Valley Diagnostics Valley Diagnostics is a Welsh company developing next‑generation lateral flow diagnostic t...

The conversations on this week’s podcast are with Vibhor Gupta, director and founder of Pangaea Data, and endogene.bio CEO María Teresa Pérez Zaballos. Times: 03:09 Pangaea Data 23:43 endogene.bio Endogene.bio endogene.bio is a precision medicine company based in France developing a non-invasive diagnostic for endometriosis. The company’s aim is to apply precision medicine to female health. The co...

This week, we chat with Affibody CEO David Bejker, and Martin Gleave, founder and chief medical officer at Sustained Therapeutics. Times: 03:47 Affibody 23:28 Sustained Therapeutics Sustained Therapeutics A spin-out from the University of British Columbia in Canada, Sustained Therapeutics utilises a proprietary polymer gel technology to develop locally injected, long-acting medications. The platfo...

This week, we chat with Pan Cancer T CEO Dr. Rachel Abbott, about – among other things – triple-negative breast cancer. We also have a conversation with Erik Manting, CEO of immunotherapy company Mendus, and Janet Hoogstraate, CEO of the CDMO helping them, North X Biologics. Times: 03:56 Pan Cancer T 20:23 Mendus/NorthX Biologics Mendus Mendus is a Swedish–Dutch immuno-oncology company developing...

This week, we have a conversation with Lisa Guerrettaz, executive director, Pharmacology and Translational Science at Artiva Biotherapeutics; and Avacta Therapeutics’ CEO Christina Coughlin. Times: 04:12 Artiva Biotherapeutics 21:30 Avacta Therapeutics Artiva Biotherapeutics Artiva Biotherapeutics is a clinical‑stage cell therapy company developing off‑the‑shelf (allogeneic) natural killer (NK) ce...